Study on the Relationship Between Hepatitis B Virus Infection in Pregnant Women and Adverse Pregnancy Outcomes

Zhi-Hao Huang
Department of Infectious Diseases, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510000

Ting-Ting Peng
Department of Infectious Diseases, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510000

Sheng-Guang Yan
School of Public Health, North China University of Science and Technology, Tangshan, 063210

Dong-Dong Yu
Department of Traditional Chinese Medicine, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510150

Jun-Chao Qiu
Department of Obstetrics, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510000

Mei-Ling Liu
School of Public Health, Department of Preventive Medicine, Guangzhou Medical University, Guangzhou, 510000

Xin-Yue Huang
School of Public Health, Department of Preventive Medicine, Guangzhou Medical University, Guangzhou, 510000

Guo-Jun Xu
School of Public Health, Department of Preventive Medicine, Guangzhou Medical University, Guangzhou, 510000

Shi Ou-Yang (ouyangshi@gzhmu.edu.cn)
Department of Infectious Diseases, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510000

Research Article

Keywords: Hepatitis B virus, Adverse pregnancy outcome, Viral load, HBeAg

DOI: https://doi.org/10.21203/rs.3.rs-144411/v1

License: ☎️ This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Objective: Aim to the relationship between adverse pregnant outcomes with chronic hepatitis B virus (HBV) infection in pregnant women. Simultaneously, assess the incidence of adverse pregnancy outcomes (APO) among different serum HBV status in pregnant women.

Method: From 2017 to 2019, we studied HBsAg (+) pregnant women and HBsAg (-) who gave birth at our hospital in Guangzhou City, China. We compared of the incidence of pregnant women with HBsAg(+) or HBsAg(-). Further, among HBsAg(+) pregnant women, we compared of the incidence of pregnant women with HBeAg(+) group or HBeAg(-) group, high HBV DNA loads (HBV DNA≥2×10^5IU/mL) group or low HBV DNA loads (HBV DNA<2×10^5IU/mL) group, respectively. Finally, multivariate logistic regression analysis was used to evaluate the independent association between HBV infection and the risk of developing APO.

Result: First, our research indicates that the rates of gestational diabetes mellitus (GDM), intrahepatic cholestasis of pregnancy (ICP), premature rupture of membrane (PROM), Fetal distress (FD), Oligohydramnios, Premature delivery (PD), Low birth weight (LBW), Meconium contamination (MC), Neonatal hyperbilirubinemia (NH) in HBsAg(+) group were higher than those in HBsAg(-) group (P<0.05). Second, among 711 HBsAg(+) pregnant women, the rates of GDM and ICP in high loads of HBV DNA were higher than those in low loads of HBV DNA group (P<0.05). Similarly, the rates of ICP in HBeAg(+) group were higher than those in HBeAg(-) group. Further, through multivariable logistical regression model analysis, we observed maternal HBsAg carrier (OR, 6.758; 95% CI, 2.358-19.369) had an independent risk for ICP. Similarly, HBsAg carrier (OR, 1.101; 95% CI, 1.066-1.137), advanced age (OR, 1.407; 95% CI, 1.016-1.137), and abortion (OR, 1.446; 95% CI, 1.062-1.969) had independent risk for GDM.

Conclusions: Chronic HBV infection can increase the rate of host adverse pregnancy outcomes (APO). The maternal viral load and HBeAg status were significantly associated with the incidence of GDM and ICP. Maternal HBsAg carrier had an independent risk for GDM and ICP.

Introduction

Chronic hepatitis B (CHB) remains an important public health problem, with approximately 240 million HBV-infected individuals worldwide[1,2]. Among those with CHB infection, approximately 15–40% will further develop more harmful complications such as cirrhosis, liver failure or even hepatoma[3]. According to the World Health Organization (WHO) statistical report, China is one of the major endemic areas for CHB infection, where the prevalence of CHB in individuals under 60 years old is 7.2% [4]. Many studies show that the infection rate of hepatitis B virus is at a high level in Chinese fertile women, around 6.7–8%[5,6]. Previous studies on CHB infection in pregnant women mostly focused on vertical mother-to-child transmission (vMTCT), and viral load was considered to be the biggest risk factor affecting vMTCT. However, there were few studies on whether CHB infection had an impact on the occurrence of APO[7,8].

Besides the impact of CHB on vMTCT, existing studies have shown that there is a correlation between pregnancy complicated with HBV infection and the occurrence of APO. HBV infection increases the risk of complications such as PD and GDM[9,10,11]. But, some scholars do not support this view[12,13]. Therefore, whether pregnancy with CHB infection increases the risk of APO is full of controversy.

In addition, existing studies on pregnant patients with HBV infection and APO are insufficient. First, most studies analyze APO from a single aspect (HBsAg positive, HBeAg positive, or DNA viral load); Secondly, in terms of DNA viral load analysis, the lower limit of clinical detection (100IU/ml) is mostly used as the grouping basis, lacking clinically common indicators with high viral load (over 2×10^5IU/mL). Furthermore, because the influencing factors of APO are complex and diverse, most studies have not further evaluated the other related influencing factors except HBV infection for APO. Finally, most of the studies were based on methods such as case-control studies and retrospective cohort studies, lacking prospective clinical observation studies.

Considering the above deficiencies, this article conducted a prospective hospital-based cohort study. The objective was to further confirm the influence of HBsAg, viral load and HBeAg in early pregnancy on APO. To explore the risk factors for APO; To further guide clinical management of pregnant women with HBV infection, and to provide ideas and basis for other related studies.
Methods

Study Design and Participant Population

From January 2017 through December 2019, after signing the informed consent, 740 individuals were included in each group of HBsAg(+) and HBsAg(-), and there were 29 HBsAg (+) pregnant women who were lost to follow-up after 6 weeks postpartum, while 65 HBsAg (-) pregnant women who dropped out or lost to follow-up. Finally, we recruited a total of 1386 pregnant women who gave birth at our hospital in Guangzhou, China. Including 711 HBsAg-positive and 675 HBsAg-negative mothers were studied. 151 of the 711 HBsAg-positive women also had high loads of HBV DNA (over $2 \times 10^5$ IU/mL), 189 of the 711 HBsAg-positive women had HBeAg-positive. The clinical records of the two groups were retrieved, including age, prenatal weight, parity, history of abortion, newborn sex. From 14 weeks of pregnancy to postpartum week 6, All the mothers were followed.

Eligible participants were pregnant women, 12–14 weeks of pregnancy, who had chronic HBV infection. The exclusion criteria were the following: co-infection with hepatitis C virus (HCV), hepatitis D virus (HDV), human immunodeficiency virus (HIV), epstein-barr virus(EBV), human herpes virus (HHV),cytomegalovirus (CMV), rubella virus (RUV), Smoking or Drinking, evidence of hepatocellular carcinoma or liver decompensation, a history of Diabetes, high blood pressure, heart disease or renal dysfunction.

Detection

HBsAg-positive women were used to Examine HBV serum markers (HBsAg, anti-HBs, HBeAg, anti-HBe, and anti-HBc) were quantified by the Abbott ARCHITECT HBsAg, anti-HBs, HBeAg, anti-HBe, and anti-HBc assays, respectively, (detection limits: 1.00 s/co, 10.00 IU/L, 1.00 s/co, 1.00 s/co and 1.00 s/co, respectively; Abbott Laboratories, Chicago, USA). The HBV DNA load was measured by a real-time PCR-based (detection limit: 100 IU/mL, Da’an Gene Co. Ltd., Sun Yat-Sen University, Guangdong, China).

Statistical Analyses

The baseline characteristics of the patients were reported with the use of descriptive statistics, which includes percentages. In univariate analyses, categorical data were compared by chi-square tests was used to assess the homogeneity of the odds ratios (ORs) and 95% confidence intervals (CIs). logistic regression analysis was used to analyze the association between HBsAg positivity and ICP or GDM. $P$ values of less than 0.05 were assessd to be of statistical signicance. All analyses was performed using the SPSS version 22.0 software (IBM, NY, USA).

Results

We compared the incidence of adverse pregnancy outcomes under different conditions (Fig. 1), the specific results are as follow.

Maternal features and incidence of adverse pregnancy outcomes with respect to HBsAg status

No statistically significant differences in the percentage of age, prenatal weight, parity, history of abortion, newborn sex use were observed between the two groups ($P>0.05$) (Table 1). Compared with the HBsAg-negative, maternal HBsAg carriers had higher incidences of adverse pregnancy outcomes, including GDM (17.4% vs 11.9%), ICP(4.1% vs 0.7%), PROM (22.1% vs 14.7%), FD (7.5% vs 3.1%), OLI (14.1% vs 8.0%), PD (6.5% vs 3.5%), LBM (8.9% vs 5.6%), MC (10.3% vs 6.2%),NH (20.3% vs 11.9%). And no statistically significant differences in the incidence of PIH(2.1% vs 2.2%), PE (2.9% vs 1.5%), ECL (0.3% vs 0), PH (1.9% vs 1.3%), PP (1.1% vs 0.4%), STI (0.6% vs 1.6%), FM (3.5% vs 2.0%), CM (0.4% vs 0) were found between the two groups($P>0.05$) (Table 1).
Table 1: Comparison of the baseline and incidence of adverse pregnancy outcomes between HBsAg(-) and HBsAg(+) pregnant women

|                         | HBsAg(-) | HBsAg(+) | P     |
|-------------------------|----------|----------|-------|
| **Baseline**            |          |          |       |
| AgeH                    | 100(14.8%) | 131(18.1%) | 0.096 |
| BMIH                    | 167(25.2%) | 156(22.7%) | 0.279 |
| NopF                    | 330(48.9%) | 339(46.9%) | 0.454 |
| HomY                    | 239(35.4%) | 253(35.0%) | 0.871 |
| FsB                     | 371(55.0%) | 393(54.4%) | 0.820 |
| **Gestational complications** |          |          |       |
| PIH                     | 15(2.2%)  | 15(2.1%)  | 0.849 |
| PE                      | 10(1.5%)  | 21(2.9%)  | 0.071 |
| ECL                     | 0(0%)     | 2(0.3%)   | 0.500 |
| GDM                     | 80(11.9%) | 126(17.4%) | 0.003 |
| ICP                     | 5(0.7%)   | 30(4.1%)  | <0.001|
| PH                      | 9(1.3%)   | 14(1.9%)  | 0.376 |
| PP                      | 3(0.4%)   | 8(1.1%)   | 0.162 |
| PROM                    | 99(14.7%) | 160(22.1%) | <0.001|
| FD                      | 21(3.1%)  | 54(7.5%)  | <0.001|
| OLI                     | 54(8.0%)  | 102(14.1%)| <0.001|
| STI                     | 11(1.6%)  | 4(0.6%)   | 0.051 |
| PD                      | 23(3.5%)  | 47(6.5%)  | 0.010 |
| LBW                     | 37(5.6%)  | 64(8.9%)  | 0.018 |
| FM                      | 13(2.0%)  | 25(3.5%)  | 0.086 |
| MC                      | 41(6.2%)  | 74(10.3%) | 0.006 |
| NH                      | 78(11.9%) | 145(20.3%)| <0.001|
| CM                      | 0(0%)     | 3(0.4%)   | 0.969 |

* Age ≥ 35Y (AgeH); BMI ≥ 28kg/m² (BMIH); Number of pregnancies: first pregnancy (NopF); History of miscarriage: yes (HomY); fetus's sex: boy (FsB); pregnancy-induced hypertension (PIH); pre-eclampsia (PE); eclampsia (ECL); gestational diabetes mellitus (GDM); intrahepatic cholestasis of pregnancy (ICP); postpartum hemorrhage (PH); placenta previa (PP); premature rupture of membrane (PROM); Fetal distress (FD); oligohydramnios (OLI); stillbirth (STI); Premature delivery (PD); Low birth weight (LBW); fetal macrosomia (FM); Meconium contamination (MC); Neonatal hyperbilirubinemia (NH); congenital malformations (CM)

Incidence of adverse pregnancy outcomes with respect to virological traits of hepatitis B virus infection in pregnant women

First, HBsAg-positive pregnant women were classified into two groups: group 1, high loads of HBV DNA (over $2 \times 10^5$ IU/mL) and group 2, low HBV DNA loads. Incidences of ICP in HBsAg-positive pregnant women with high HBV DNA loads and low HBV DNA loads were 10.6% and 2.5%, respectively. Similarly, Incidences of GDM were 23.2% and 16.1%, respectively. A significantly higher Incidences of ICP and GDM were found in group 1 compared to group 2. These differences were statistically significant (Table 2).
Table 2
The incidence of pregnancy outcomes with different viral load in HBsAg(+) pregnant women

| Gestational complications | HBVDNA < 2×10^5 IU/mL | HBVDNA ≥ 2×10^5 IU/mL | P   |
|---------------------------|------------------------|------------------------|-----|
| GDM                       | 90(16.1%)              | 35(23.2%)              | 0.042|
| ICP                       | 14(2.5%)               | 16(10.6%)              | < 0.001|
| PROM                      | 118(21.1%)             | 41(27.2%)              | 0.111|
| FD                        | 41(7.3%)               | 12(7.9%)               | 0.795|
| OLI                       | 78(13.9%)              | 23(15.2%)              | 0.684|
| PD                        | 37(6.6%)               | 10(6.7%)               | 0.976|
| LBW                       | 55(9.9%)               | 9(6.0%)                | 0.146|
| MC                        | 62(11.2%)              | 11(7.4%)               | 0.180|
| NH                        | 113(20.4%)             | 30(20.1%)              | 0.944|

Second, HBsAg-positive pregnant women were classified into two groups: group 3 (HBeAg-positive) and group 4 (HBeAg-negative). Incidences of ICP in Group 3 was approximately four times higher than Group 4. These differences were statistically significant (Table 3).

Table 3
The incidence of adverse pregnancy outcomes with different HBeAg states in HBsAg(+) pregnant women

| Gestational complications | HBeAg(-) | HBeAg(+) | P   |
|---------------------------|----------|----------|-----|
| GDM                       | 90(17.2%)| 35(18.5%)| 0.693|
| ICP                       | 13(2.5%) | 17(9.0%) | < 0.001|
| PROM                      | 120(23.0%)| 39(20.6%)| 0.506|
| FD                        | 39(7.5%) | 14(7.4%) | 0.977|
| OLI                       | 73(14.0%)| 28(14.8%)| 0.779|
| PD                        | 35(6.7%) | 12(6.5%) | 0.914|
| LBW                       | 50(9.6%) | 14(7.6%) | 0.405|
| MC                        | 58(11.2%)| 15(8.1%) | 0.243|
| NH                        | 107(20.7%)| 36(19.5%)| 0.728|

Univariate and multivariate logistic regression analyses of factors related to ICP and GDM

Among the 1386 pregnant women enrolled, 35 (2.5%) were ICP patient. HBsAg carriage were observed with the increased incidence of ICP, with an OR value of 5.801 (95% CI 2.237–15.04). But in Age (OR 1.046 95% CI 0.429–2.55), BMI, NOP (OR 0.916 95% CI 0.467–1.796), HOM (OR 0.731 95% CI 0.348–1.535), SU (OR 1.232 95% CI 0.532–2.853), HOAP (OR 0.974 95% CI 0.965–0.98) and PIH, there was no significant difference between the mothers with ICP and those without. (Table 4). Similarly, 206 were GDM patient in pregnant women, Age, NOP, HOM and HBsAg carriage were associated with the increased incidence of GDM, with an OR value of 2.952 (95% CI 2.11–4.131), 0.713 (95% CI 0.528–0.963), 1.643 (95% CI 1.211–2.204) and 1.567 (95% CI 1.158–2.12). And there was no significant difference in BMI, SU, HOAP and PIH between pregnant women with GDM and without GDM. (Table 5).
|                  | None-ICP(n%) | ICP(n%) | χ² | P   | OR   | 95%CI          |
|-----------------|-------------|---------|----|-----|------|----------------|
| **Age**         |             |         |    |     |      |                |
| < 35Y           | 1138(83.5%) | 29(82.9%) | 0.010 | 0.920 | 1.046 | 0.429–2.550 |
| ≥ 35Y           | 225(16.5%)  | 6(17.1%)  |     |     |      |                |
| **BMI**         |             |         |    |     |      |                |
| 18.5–23.9       | 340(25.8%)  | 10(30.3%) | 0.375 | 0.829 | -     | -             |
| 24.0–27.9       | 662(50.2%)  | 16(48.5%) |     |     |      |                |
| ≥ 28            | 316(24.0%)  | 7(21.2%)  |     |     |      |                |
| **Nop**         |             |         |    |     |      |                |
| None            | 710(52.1%)  | 19(54.3%) | 0.066 | 0.797 | 0.916 | 0.467–1.796 |
| first pregnancy | 653(47.9%)  | 16(45.7%) |     |     |      |                |
| **Hom**         |             |         |    |     |      |                |
| None            | 881(64.6%)  | 25(71.4%) | 0.690 | 0.406 | 0.731 | 0.348–1.535 |
| Yes             | 482(35.4%)  | 10(28.6%) |     |     |      |                |
| **SU**          |             |         |    |     |      |                |
| None            | 1133(83.1%) | 28(80.0%) | 0.237 | 0.627 | 1.232 | 0.532–2.853 |
| Yes             | 230(16.9%)  | 7(20.0%)  |     |     |      |                |
| **HOAP**        |             |         |    |     |      |                |
| None            | 1288(94.5%) | 35(100%)  | -  | *0.255 | 0.974 | 0.965–0.98 |
| Yes             | 75(5.5%)    | 0(0%)    |     |     |      |                |
| **PIH**         |             |         |    |     |      |                |
| None            | 1333(97.8%) | 35(100%)  | -  | *1.000 | -     | -             |
| Yes             | 30(2.2%)    | 0(0%)    |     |     |      |                |
| **HBsAg**       |             |         |    |     |      |                |
| Negative        | 670(49.2%)  | 5(14.3%)  | 16.617 | <0.001 | 5.801 | 2.237–15.04 |
| Positive        | 693(50.8%)  | 30(85.7%) |     |     |      |                |

*: Fisher #: Chi-square Test Correction formula

Scar uterus (SU); histories of abnormal pregnancy (HOAP)
Table 5
Single facto regression analysis of gestational diabetes mellitus

|                | None-GDM(n%) | GDM(n%) | $\chi^2$ | P      | OR    | 95%CI     |
|----------------|--------------|---------|----------|--------|-------|-----------|
| Age < 35Y      | 1027(86.2%)  | 140(68.0%) | 42.619  | < 0.001 | 2.952 | 2.110–4.131 |
| Age $\geq$ 35Y | 164(13.8%)   | 66(32.0%)  |          |        |       |           |
| BMI 18.5–23.9  | 300(26.0%)   | 50(25.4%)  | 1.595   | 0.450  | -     |           |
| BMI 24.0–27.9  | 584(50.7%)   | 93(47.2%)   |         |        |       |           |
| BMI $\geq$ 28  | 269(23.3%)   | 54(27.4%)   |         |        |       |           |
| Nop None       | 606(50.9%)   | 122(59.2%)  | 4.897   | 0.027  | 0.713 | 0.528–0.963 |
| Nop first preg | 585(49.1%)   | 84(40.8%)   |         |        |       |           |
| Hom None       | 792(66.5%)   | 113(54.9%)  | 10.437  | 0.001  | 1.634 | 1.211–2.204 |
| Hom Yes        | 399(33.5%)   | 93(45.1%)   |         |        |       |           |
| SU None        | 996(83.6%)   | 164(79.6%)  | 2.010   | 0.156  | 1.308 | 0.902–1.898 |
| SU Yes         | 195(16.4%)   | 42(20.4%)   |         |        |       |           |
| HOAP None      | 1129(94.8%)  | 193(93.7%)  | 0.422   | 0.516  | 1.227 | 0.662–2.273 |
| HOAP Yes       | 62(5.2%)     | 13(6.3%)    |         |        |       |           |
| PIH None       | 1166(97.9%)  | 201(97.6%)  | 0.090   | 0.764  | 1.160 | 0.439–3.066 |
| PIH Yes        | 25(2.1%)     | 5(2.4%)     |         |        |       |           |
| HBsAg Negative | 594(49.9%)   | 80(38.8%)   | 8.571   | 0.003  | 1.567 | 1.158–2.12  |
| HBsAg Positive | 597(50.1%)   | 126(61.2%)  |         |        |       |           |

To judge whether HBsAg carriage was an independent risk factor for GDM or ICP, A multivariable logistic regression analysis was used in our study. Maternal HBsAg carriage was an independent risk factor for ICP, with an OR value of 7.758(95%CI 2.358–19.369). (Table 6). But a significant association of age, HOM and maternal HBsAg carriage with the increased risk of GDM was discovered, with an OR value of 1.101 (95%CI 1.066–1.137), 1.407 (95%CI 1.066–1.137) and 1.446 (95%CI 1.062–1.969), respectively. (Table 7)

Table 6
Logistic multivariate regression analysis of intrahepatic cholestasis during pregnancy

|       | B    | S.E  | Wald | P     | OR    | 95%CI     |
|-------|------|------|------|-------|-------|-----------|
| HBsAg | 1.911| 0.537| 12.647| < 0.001 | 6.758 | 2.358–19.369 |
Logistic multivariate regression analysis of gestational diabetes mellitus

|    | B     | S.E  | Wald  | P      | OR    | 95%CI          |
|----|-------|------|-------|--------|-------|---------------|
| Age| 0.096 | 0.016| 34.487| < 0.001| 1.101 | 1.066–1.137   |
| Hom| 0.342 | 0.158| 4.690 | 0.030  | 1.407 | 1.033–1.917   |
| HBsAg| 0.369| 0.158| 5.476 | 0.019  | 1.446 | 1.062–1.969   |

**Discussion**

CHB is still one of the major infectious diseases in the world. Previous studies on HBV infection in pregnant women mainly focus on vMTCT, but there were few studies on whether CHB infection had an impact on the occurrence of APO.

The existing research results show that there is a correlation between HBV infection in pregnancy with APO. HBV infection increases the incidence of PD, GDM, LBW [9,10,11], which is consistent with our findings. The reason why CHB infection increases the incidence of some APO may be related to the effect of HBV virus on liver function of inactivating enzymes and hormones. During pregnancy, women produce more endogenous hormones, which will put a heavier burden on the liver. The virus damages hepatocytes, which leads to a relatively high level of estrogen. High level of estrogen will lead to APO[14]. Furthermore, when the placenta and fetal membranes are infected by HBV, the chorionic vessels will change accordingly, causing the blood circulation of the placenta to drop. Reduced intrauterine blood oxygen supply will also increase the risk of APO [15].

It is noteworthy that further analysis in this study found that the incidence of GDM and ICP in HBsAg(+) pregnant women with high viral load (2×10^5IU/ml) and HBeAg(+) were higher than their control group. This may be related to the maternal excessive inflammatory response. Existing studies have shown that maternal excess inflammation increases the risk of complications during pregnancy [16,17]. HBeAg is a marker of active HBV replication[18]. There was a strong inflammatory response in HBV infected patients with HBeAg (+) or high load of HBV DNA [19,20]. HBV DNA load is an important marker to predict the course of severe complications from HBV immune tolerance [19,21]. Chronic inflammation caused by HBV is associated with insulin resistance. In HBV infected patients, the insulin resistance level is significantly higher than the normal population [22]. In addition, HBsAg and HBV DNA were found in the pancreas of patients infected with HBV. These suggest that HBV may cause damage to pancreatic tissue, leading to insufficient insulin secretion [23].

Logistic model was established to analyze the influencing factors of APO and it was found that CHB infection could be an independent risk factor for ICP. Many studies also showed that the risk of ICP in pregnant women was higher when HBeAg was positive[24,25]. We think this may be related to the downgrading of the expression of NTCP(sodium taurocholate cotransporting polypeptide). Human NTCP has been identified as a functional receptor for HBV. HBV can mediate the infection through the specific binding of surface antigen[26,27,28]. Meanwhile, NTCP is responsible for the transmembrane transport of sodium and bile acids in liver cells, and is responsible for about 80% of bile acid reuptake[29]. NTCP can transport bile acids to hepatocytes in the enterohepatic circulation and play an important role in the hepatenteric circulation of cholic acid to maintain the dynamic balance of bile acids. Some studies have suggested that defects in NTCP may lead to intractable hyperbile acidemia [30,31]. In patients with CHB, hepatocytes are constantly destroyed and multiplied. In proliferative hepatocytes, the NTCP expression on cell membrane is decreasing [32]. Moreover, existing research suggest that, ICP is related to PGE2(prostaglandin E2), which will affects the function of natural killer cells [33,34]; Mutations in genes associated with drug resistance(such as ABCB 11[35],ABCC 2[36],ABCB 4[37,38,NR1H4 [39]).

To sum up, pregnancy with HBV infection is a serious threat to maternal and child health. It is necessary to pay attention to the health education of pregnant women, the HBV DNA in early pregnancy and the regular examination of liver function during pregnancy especially the related examination of gestational diabetes and cholestasis). Consulting about potential risks as well as focusing on antenatal surveillance for APO in HBV-infected pregnant women may be necessary.
Declarations

Ethics approval and consent to participate

The experimental protocol was established, according to the ethical guidelines of the Helsinki Declaration and was approved by the Human Ethics Committee of The Fifth Affiliated Hospital of Guangzhou Medical University. Written informed consent was obtained from individual or guardian participants.

Consent for publication

Not applicable

Availability of data and materials

All data generated or analysed during this study are included in this published article

Competing interests

The authors declare that they have no competing interests.

Funding

This study was supported in part by grants from the National Natural Science Foundation of China (Grant No.81803884), the Natural Science Foundation of Guangdong Province, China (Grant No.2015A030313684), and the Scientific research project of Guangdong Provincial Bureau of Traditional Chinese Medicine (Grant No.20191215)

Authors' contributions

Zhi-Hao Huang, Shi Ou-Yang, Ting-Ting Peng, Jun-Chao Qiu, Dong-Dong Yu developed the concept of the study, Mei-Ling Liu, Xin-Yue Huang, Guo-Jun Xu participated in its design and coordination and helped draft the manuscript. Ting-Ting Peng, Zhi-Hao Huang, Sheng-Guang Yan contributed to the acquisition and interpretation of data. Shi Ou-Yang, Jun-Chao Qiu provided a critical review and substantially revised the manuscript. All authors read and approved the final manuscript.

Acknowledgments

Not applicable

References

[1] Trépo C, Chan HL, Lok A. Hepatitis B virus infection [J]. Lancet. 2014, 384(9959): 2053.

[2] Zahn G, Greischel A. The impact of vaccination and antiviral therapy on hepatitis B and hepatitis D epidemiology. [J]. PlosOne. 2014, 9(10): e110143.

[3] Asl L. Chronic hepatitis B [J]. NEnglJMed. 2002(346): 1682-1683.

[4] Liang X, Bi S, Yang W, et al. Reprint of: Epidemiological serosurvey of Hepatitis B in China—declining HBV prevalence due to Hepatitis B vaccination. [J]. Vaccine. 2013, 31Suppl9(47): J21.

[5] Lao T T, Sahota D S, Law LW, et al. Age-specific prevalence of hepatitis B virus infection in young pregnant women, Hong Kong Special Administrative Region of China [J]. Bulletin of the World Health Organization. 2014, 92(11): 782.

[6] Zhang L, Gui X, Fan J, et al. Breast feeding and immunoprophylaxis efficacy of mother-to-child transmission of hepatitis B virus [J]. J Matern Fetal Neonatal Med. 2014, 27(2): 182-186.
[7] Wen W H, Lai M W, Chang M H. A review of strategies to prevent mother-to-infant transmission of hepatitis b virus infection [J]. Expert Review of Gastroenterology & Hepatology. 2016, 10(3): 317-330.

[8] Han L, Zhang H W, Xie J X, et al. A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus [J]. World journal of gastroenterology: WJG, 2011, 17(38): 4321.

[9] Lao T T, Sahota DS, Cheng Y K, et al. Maternal hepatitis B surface antigen status and incidence of pre-eclampsia [J]. J Viral Hepat, 2013, 20(5): 343-349.

[10] Safir A, Levy A, Sikuler E, et al. Maternal hepatitis B virus or hepatitis C virus carrier status as an independent risk factor for adverse perinatal outcome [J]. Liver International. 2010, 30(5): 765-770.

[11] Z W, A Z, H Z, et al. Maternal Hepatitis B Virus Infection and Pregnancy Outcomes: A Hospital-based Case-control Study in Wuhan, China [J]. Journal of Clinical Gastroenterology. 2017, 52: 1.

[12] Li J G P, Jr J M M, Summers P R. The effect of hepatitis B antigenemia on pregnancy outcome [J]. American Journal of Obstetrics & Gynecology. 1988, 158(1): 486-489.

[13] Wong S, Chan L Y, Yu V, et al. Hepatitis B carrier and perinatal outcome in singleton pregnancy [J]. American journal of perinatology, 1999, 16(09): 0485-0488.

[14] Armistead B, Johnson E, VanderKamp R, et al. Placental regulation of energy homeostasis during human pregnancy [J]. Endocrinology, 2020, 161(7): bqaa076.

[15] Luo L, Wu J, Qu Y, et al. Association between maternal HBsAg carrier status and neonatal adverse outcomes: meta-analysis [J]. The Journal of Maternal-Fetal & Neonatal Medicine, 2015, 28(11): 1308-1317.

[16] Girard S, Heazell AE, Derricott H, et al. Circulating cytokines and alarmins associated with placental inflammation in high-risk pregnancies [J]. Am J Reprod Immunol, 2014, 72(4): 422-434

[17] Cotechini T, Komisarenko M, Sperou A, et al. Inflammation in rat pregnancy inhibits spiral artery remodeling leading to fetal growth restriction and features of preeclampsia [J]. J Exp Med, 2014, 211(1): 165-179.

[18] Feld JJ, Heathcote EJ. Hepatitis B e antigen- positive chronic hepatitis B: natural history and treatment [J]. Semin Liver Dis, 2006, 26(2): 116-129.

[19] Yu SJ, Kim YJ. Hepatitis B viral load affects prognosis of hepatocellular carcinoma [J]. World J Gastroenterol, 2014, 20(34): 12039-12044.

[20] Chen L, Zhang Q, Chang W, et al. Viral and host inflammation-related factors that can predict the prognosis of hepatocellular carcinoma [J]. Eur J Cancer, 2012, 48(13): 1977-1987.

[21] Patton H, Tran TT. Management of hepatitis B during pregnancy [J]. Nat Rev Gastroenterol Hepatol, 2014, 11(7): 402-409.

[22] Gomes C P, Torloni M R, Gueuvoghlanian-Silva B Y, et al. Cytokine levels in gestational diabetes mellitus: a systematic review of the literature [J]. American Journal of Reproductive Immunology, 2013, 69(6): 545-557.

[23] Shimoda T, Shikata T, Karasawa T, et al. Light microscopic localization of hepatitis B virus antigens in the human pancreas. Possibility of multiplication of hepatitis B virus in the human pancreas [J]. Gastroenterology, 1981, 81(6): 998-1005.

[24] Geenes V, Williamson C. Intrahepatic cholestasis of pregnancy. World J Gastroenterol 2009;15:2049–66.

[25] Tan J, Liu X, Mao X, et al. HBsAg positivity during pregnancy and adverse maternal outcomes: a retrospective cohort analysis [J]. Journal of viral hepatitis, 2016, 23(10): 812-819.
[26] Shimura S, Watashi K, Fukano K, et al. Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity. J Hepatol 2017;66:685–92.

[27] Wang H, Shang X, Wan X, et al. Increased hepatocellular carcinoma risk in chronic hepatitis B patients with persistently elevated serum total bile acid: a retrospective cohort study. Sci Rep 2016;6:38180.

[28] Haag M, Hofmann U, Murdter TE, et al. Quantitative bile acid profiling by liquid chromatography quadrupole time-of-flight mass spectrometry: monitoring hepatitis B therapy by a novel Na(+)taurocholate cotransporting polypeptide inhibitor. Anal Bioanal Chem 2015;407:6815–25.

[29] Slijepcevic D, van de Graaf S F J. Bile acid uptake transporters as targets for therapy[J]. Digestive diseases, 2017, 35(3): 251-258.

[30] Alrefai WA, Gill RK. Bile acid transporters: structure, function, regulation and pathophysiological implications[J]. Pharm Res, 2007, 24(10): 1803-1823.

[31] Thomas C, Pellicciari R, Pruzanski M, et al. Targeting bile-acid signalling for metabolic diseases[J]. Nat Rev Drug Discov, 2008, 7(8): 678-693.

[32] Yan Y, Allweiss L, Yang D, et al. Down-regulation of cell membrane localized NTCP expression in proliferating hepatocytes prevents hepatitis B virus infection[J]. Emerging microbes & infections, 2019, 8(1): 879-894.

[33] Zhang M, Wang F, Chong Y, et al. Liver myofibroblasts from hepatitis B related liver failure patients may regulate natural killer cell function via PGE2. J Transl Med 2014;12:308.

[34] Eloranta ML, Heinonen S, Mononen T, et al. Risk of obstetric cholestasis in sisters of index patients. Clin Genet 2001;60:42–5.

[35] Pan S, Li X, Jiang P, et al. Variations of ABCB4 and ABCB11 genes are associated with primary intrahepatic stones. Mol Med Rep 2015;11:434–46.

[36] Sookoian S, Castano G, Burgueno A, et al. Association of the multidrug-resistance-associated protein gene (ABCC2) variants with intrahepatic cholestasis of pregnancy. J Hepatol 2008;48:125–32.

[37] Mullenchach R, Linton KJ, Wiltshire S, et al. ABCB4 gene sequence variation in women with intrahepatic cholestasis of pregnancy. J Med Genet 2003;40:e70.

[38] Bacq Y, Gendrot C, Perrotin F, et al. ABCB4 gene mutations and single-nucleotide polymorphisms in women with intrahepatic cholestasis of pregnancy. J Med Genet 2009;46:711–5.

[39] Davit-Spraul A, Gonzalez E, Jacquemin E. NR1H4 analysis in patients with progressive familial intrahepatic cholestasis, drug-induced cholestasis or intrahepatic cholestasis of pregnancy unrelated to ATP8B1, ABCB11 and ABCB4 mutations. Clin Res Hepatol Gastroenterol 2012;36:569–73.